Active, not recruitingPHASE1, PHASE2NCT03598595

Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma

Studying Osteosarcoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
M.D. Anderson Cancer Center
Principal Investigator
John A Livingston
M.D. Anderson Cancer Center
Intervention
Docetaxel(drug)
Enrollment
31 enrolled
Eligibility
12 years · All sexes
Timeline
20192026

Study locations (1)

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03598595 on ClinicalTrials.gov

Other trials for Osteosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Osteosarcoma

← Back to all trials